Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Psoriasis: Update Bulletin [October 2016]

Product Code:
Publication Date:
October 2016

Gain new KOL insights on the latest events happening in psoriasis: Johnson & Johnson present the Phase III (VOYAGE 1) data of guselkumab, the experimental IL-23 monoclonal antibody being co-developed with MorphoSys; SunPharma announces positive Phase III (reSURFACE 1 and 2) data for its investigational IL-23p19 inhibitor, tildrakizumab; Can-Fite submitted Phase III clinical trial protocol for piclidenoson (CF101) to the EMA in the first half of 2016. The first-in-class orally bioavailable, adenosine receptor agonist (A3AR) will be evaluated in Phase II/III clinical studies against Otezla.

Highlights from this event update bulletin

  • How impressed are the KOLs by the Phase III VOYAGE 1 data for guselkumab?
  • Where is guselkumab being considered for use in the psoriasis treatment strategy and which treatments might it replace?
  • How do KOLs view the Phase III reSURFACE 1 and 2 data for tildrakizumab?
  • Given the emergence of multiple IL-23 inhibitors, how successful do KOLs think tildrakizumab will be in the psoriasis market?
  • What concerns do KOLs have about Can-Fite’s piclidenoson?
  • Which combinations offer the best potential with piclidenoson in the treatment of psoriasis?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved